Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acacia Research

This article was originally published in The Gray Sheet

Executive Summary

Majority owner of biological array processor developer CombiMatrix announces the closing of a $19 mil. round of private equity financing Jan. 23. Proceeds from the offering will go toward maintaining a majority stake in CombiMatrix, which filed a registration statement with the SEC on Nov. 22 for a proposed IPO (1"The Gray Sheet" Dec. 11, 2000, p. 15). The offering price was $17.50 per unit, with each unit consisting of one share of Acacia Research stock and one three-year callable common stock purchase warrant, which entitles the holder to buy one share of Acacia stock for $21, and is callable by the firm if the stock's closing price finishes above $26.50 for 20 consecutive trading days on the Nasdaq exchange

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel